New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
Moupali Das, MD, MPH
Advertisement
Vice President, Clinical Development, HIV Prevention, and Virology Pediatrics Head at Gilead Sciences.
Articles by Moupali Das, MD, MPH
Advertisement
Latest Updated Articles
Gilead's Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 StudyPublished: March 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol
3
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
4
Risk Stratification, Testing, and Treatment in Recurrent Clostridioides difficile
5
